NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
47 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05581121 2026-02-25
PAROLA
Institut Claudius Regaud
Phase 3 Recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07413120 2026-02-17
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
Phase 3 Completed
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT03653507 2026-02-06
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06564844 2026-01-27
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT01952223 2025-07-30
PEACE2
UNICANCER
Phase 3 Active not recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT06855589 2025-03-04
PCS-XII
Charles LeMoyne Hospital
Phase 3 Not yet recruiting
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT05264896 2023-09-07
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Phase 3 Recruiting
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT05325164 2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3 Withdrawn
NCT00887536 2022-04-20
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT04384601 2021-07-19
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Ruijin Hospital
Phase 3 Not yet recruiting
NCT03536182 2021-05-26
CIPHER
University of Texas Southwestern Medical Center
Phase 3 Withdrawn
NCT01365156 2021-02-03
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00917384 2019-09-25
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Eli Lilly and Company
Phase 3 Completed
NCT01170663 2019-09-18
RAINBOW
Eli Lilly and Company
Phase 3 Completed
NCT02404363 2019-07-25
PANCREADOGREL
Assistance Publique - HĂ´pitaux de Paris
Phase 3 Terminated
NCT00096408 2019-03-20
Laparoscopic Approach to Cancer of the Endometrium
Queensland Centre for Gynaecological Cancer
Phase 3 Completed
NCT01121393 2018-12-14
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 3 Completed
NCT02125240 2018-07-16
ICWIP
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT00949650 2018-04-06
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT00404924 2016-09-30
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Sanofi
Phase 3 Completed
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed
NCT01419002 2015-07-29
Net-Pac
CHIR-Net
Phase 3 Terminated
NCT01521702 2015-03-20
NEOPAC
Institut Paoli-Calmettes
Phase 3 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT01363466 2011-06-01
Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
UNICANCER
Phase 3 Terminated
NCT00140075 2011-05-26
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Pfizer
Phase 3 Completed
NCT00455936 2010-10-25
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea
Phase 3 Completed
NCT01130233 2010-05-25
Randomized Trial on Robotic Assisted Resection for Rectal Cancer
The University of Hong Kong
Phase 3 Unknown
NCT00358566 2008-05-19
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Pharmexa A/S
Phase 3 Terminated